SL科学
估值 各估值倍数与自身5年区间的对比
同业对比 Biotechnology
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| SL科学 (SLBT) | 857.96M | -139.09 | 95.63 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 126.66B | 29.11 | 6.26 | 0.00% |
| Moderna (MRNA) | 87.04B | -27.32 | 12.87 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 81.41B | 19.57 | 2.57 | 0.46% |
| argenx SE (ARGX) | 51.51B | 31.21 | 6.12 | 0.00% |
| BeiGene (ONC) | 41.96B | 65.32 | 8.11 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算13.8%。
合理价值
SL Science Holding Ltd receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 13% discount to our quantitative fair value estimate of $1.74 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
经济护城河
The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
SL科学 讨论区 0 条评论